Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
List view / Grid view
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
A three-pronged antibody has been found to protect from infection with two strains of SHIV, better than individual natural antibodies...
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
13 April 2016 | By Victoria White, Digital Content Producer
Sanofi has opened a partnering office at Stevenage Bioscience Catalyst to engage and collaborate with the UK's network of bioscience companies and academia...
29 March 2016 | By Victoria White
Dr Yong-Jun Liu has been appointed as Sanofi’s new Head of Research, Global R&D, effective...
17 March 2016 | By Victoria White
IPROVE has launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years...
16 March 2016 | By Victoria White
Sanofi and DiCE Molecules have entered a five-year global collaboration to discover potential new therapeutics for up to 12 targets...
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...